CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 82 enrolled
Drug / intervention
Engerix-Bbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02985450
NCT02985450N/ACompleted
CompareCT.gov

A Prospective Study of Hepatitis B Virus (HBV) Immunity and Hepatitis B Vaccination in Patients With Non Alcoholic Fatty Liver Disease (NAFLD) in Canada

University of Calgary·observational·Posted Dec 7, 2016·Updated Nov 3, 2021

In Brief

An observational study evaluating Engerix-B for Non-Alcoholic Fatty Liver Disease and 2 related conditions. Completed, enrolled 82 participants across 1 site.

Detailed Summary

(1) Due to missed childhood vaccination programs, the majority of adult patients with NAFLD in Canada do not have immunity to hepatitis B. (2) Adults with NAFLD who receive the HBV vaccine have reduced immunogenic responses in the setting of obesity (i.e., protective anti-HBs titres). Aims: (1) To determine the sero-prevalence of immunity against hepatitis B in a cohort of prospectively evaluated adult NAFLD patients. (2) To prospectively determine HBV vaccine responses (anti-HBs titres) in adult NAFLD patients.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Alcoholic Fatty Liver Disease, Hepatitis B, Vaccine Reaction
CountriesCanada
CollaboratorsCanadian Institutes of Health Research (CIHR), GlaxoSmithKline

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedDec 7, 2016
Enrollment StartAug 1, 2016
Primary CompletionJan 1, 2021
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 9.6 years ago

Interventions

Engerix-Bbiological

Hepatitis B Vaccine